Platelet Membrane-Coated Nanoparticles for Unbiased CTC Enrichment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for capturing circulating tumor cells (CTCs) are limited by low specificity, heterogeneity, and the need for prior knowledge of cancer type, leading to false negatives or positives, making early detection challenging.
Innovation Solution
Utilizing platelet membrane-coated nanoparticles (PNPs) to enrich CTCs through natural interactions, combined with single cell RNA sequencing (scRNA-seq) and a novel computational framework to identify cancer type or subtype without prior information.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If positive selection based on specific surface markers (e.g., EpCAM) is used, then CTC enrichment is achieved, but false negatives occur when CTCs lose epithelial markers through EMT
Solution Approach 1:
The patent uses platelet membrane-coated nanoparticles as an intermediary to capture CTCs. The platelet membrane contains receptors that naturally recognize and bind to CTCs regardless of their epithelial marker status, serving as a universal mediator that overcomes the limitation of marker-specific antibodies
Solution Approach 2:
The platelet membrane coating provides universal binding capability across different cancer types and CTC states. Unlike EpCAM antibodies that only work for epithelial cancers, the platelet membrane receptors can bind to various CTCs including those that have undergone EMT, making the method universally applicable
2Reliability
If negative selection to remove blood cells is used, then unbiased enrichment is achieved, but non-CTC circulating cells are retained causing false positives
Solution Approach 1:
The platelet membrane-coated nanoparticles act as a selective intermediary that specifically recognizes CTCs through natural platelet-CTC interactions. This specific binding distinguishes CTCs from other circulating cells, enabling precise identification without the false positives associated with non-specific negative selection
3Measurement precision
If marker-specific methods are used, then detection sensitivity is improved for known cancer types, but prior knowledge of cancer type is required
Solution Approach 1:
The platelet membrane-coated nanoparticles enable the system to automatically detect and bind to CTCs without requiring external information about cancer type. The natural platelet-CTC interaction mechanism serves itself to recognize CTCs across all cancer types, eliminating the need for pre-specified markers or cancer type knowledge
4Quantity of substance
If conventional enrichment methods are used, then CTC capture is attempted, but low specificity leads to high background noise in scRNA-seq data
Solution Approach 1:
The platelet membrane-coated nanoparticles serve as a highly specific intermediary that selectively captures CTCs while leaving other circulating cells behind. This specific enrichment reduces background noise in downstream scRNA-seq analysis by ensuring that the enriched population consists primarily of genuine CTCs
Solution Approach 2:
The method changes the enrichment parameter from marker-specific binding to natural platelet-CTC interaction. This parameter change increases both the purity and quantity of captured CTCs, improving the signal-to-noise ratio in scRNA-seq data without requiring ultra-sensitive detection methods
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enriches CTCs from any cancer type, enabling early detection and accurate identification of cancer subtypes, overcoming the limitations of existing methods by increasing detection power and reducing noise in scRNA-seq data.
Implementation Method 1
contacting the biological sample with nanoparticles coated with a cell membrane that has a binding affinity with the target subject
Data Source
AI summary
Described are methods, compositions, and devices for early detection and prevention of diseases, including cancer, infectious diseases, and autoimmune diseases, using broad-spectrum enrichment technology and single cell sequencing technology. An example method for detecting circulating tumor cells (CTCs) using platelet membrane-coated nanoparticles (PNPs) and single cell RNA sequencing (scRNA-seq) technology is also provided.